ASCO Daily News

Dr. Ryan Nipp joins Dr. Monty Pal to discuss the high-impact cancer care delivery research presented at the 2026 ASCO Quality Care Symposium, including studies on financial navigation and decentralized clinical trials.

LINK TO FULL TRANSCRIPT

Dr. Sara Tolaney joins Dr. Monty Pal to discuss optimizing the sequencing and combination of antibody-drug conjugates for metastatic HER2-positive and triple-negative breast cancer, as well as guidelines for managing serious toxicities like ILD and neutropenia.

LINK TO FULL TRANSCRIPT

Myeloma specialists Dr. Marc Braunstein and Dr. Rahul Banerjee join Dr. Monty Pal to discuss recent breakthroughs for patients with multiple myeloma, including expert advice on how to manage side effects and identify the right treatment among a series of novel immuno- and targeted therapies.

LINK TO FULL TRANSCRIPT

Dr. Jedd Wolchok, a pioneer in melanoma research, joins Dr. Monty Pal to break down practice-changing advances in the field, including landmark 10-year CheckMate-067 survival data, safer immunotherapy dosing, and the rise of neoadjuvant treatment.

LINK TO FULL TRANSCRIPT

Dr. Monty Pal and Dr. Petros Grivas discuss the rapidly evolving management of bladder cancer, including key updates in non-muscle-invasive disease, the integration of novel therapies in the advanced setting, and practical strategies for managing toxicities in clinical practice.

LINK TO FULL TRANSCRIPT

In part two of our miniseries on the global translation gap in oncology, host Dr. Monty Pal and Dr. Regina Barragán-Carrillo explore how ASCO26 Plenary breakthroughs can be adapted to clinical practice in Latin America. Together, they address real-world implementation challenges including delayed diagnoses, finite resource allocation, and access to precision diagnostics.

LINK TO FULL TRANSCRIPT

Dr. Monty Pal and Dr. Rachna Shroff explore how GLP-1 receptor agonists impact progression and survival in GI cancers, examining current retrospective data, immune microenvironment biology, and the need for prospective trials.

LINK TO FULL TRANSCRIPT

How do we translate oncology breakthroughs into practice? In part one of a two-part miniseries, host Dr. Monty Pal and Dr. Atul Batra discuss the clinical realities, opportunities, and challenges of adapting ASCO26 Plenary findings into cancer care worldwide, using India's health care landscape as a blueprint for resource-limited settings.

LINK TO FULL TRANSCRIPT

Dr. Monty Pal and Dr. Roselle De Guzman discuss key abstracts from the 2026 ASCO Breakthrough Meeting, including the real-world impact of liquid biopsies for early multi-cancer detection, AI applications in colorectal cancer screening, and how global advances in breast, esophageal, and small cell lung cancers translate directly to diverse patient populations in the Asia-Pacific region.

LINK TO FULL TRANSCRIPT

Dr. Megan Kruse and Dr. Hope Rugo discuss practice-changing data in metastatic breast cancer and critical shifts in the treatment of early-stage disease that were presented at the 2026 ASCO Annual Meeting.

LINK TO FULL TRANSCRIPT

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss high-impact abstracts in the treatment of prostate, bladder, and kidney cancers that were presented at the 2026 ASCO Annual Meeting.

LINK TO FULL TRANSCRIPT

Dr. Pauline Funchain and Dr. Allison Betof discuss practice-changing and paradigm-shifting abstracts in melanoma, Merkel cell carcinoma, and cellular therapies that were presented at the 2026 ASCO Annual Meeting.

LINK TO FULL TRANSCRIPT

Dr. Nilo Azad and Dr. Aparna Parikh discuss high-impact studies in gastrointestinal cancers and other novel treatment approaches that were presented at the 2026 ASCO Annual Meeting.

LINK TO FULL TRANSCRIPT

Dr. Marc Braunstein and Dr. Adam Kittai highlight top research on hematologic malignancies from the 2026 ASCO Annual Meeting, including studies on lymphoid malignancies, multiple myeloma, and plasma cell disorders.

LINK TO FULL TRANSCRIPT

Dr. Christine Lovly and Dr. Vamsi Velcheti discuss practice-changing lung cancer data presented at the 2026 ASCO Annual Meeting, including key studies on squamous cell lung cancer, NSCLC, and SCLC.

LINK TO FULL TRANSCRIPT

Dr. Monty Pal shares highlights from the final day of ASCO26, including new research on treating anemia in myelofibrosis, advances in RAS-mutated mCRC, novel therapies for AML, and a potentially practice-changing trial in TNBC.

LINK TO FULL TRANSCRIPT

Dr. Monty Pal shares highlights from Day 4 of the 2026 ASCO Annual Meeting, including a much-anticipated study in hepatocellular carcinoma, new data in non–small cell lung cancer, and a key update in the treatment of Merkel cell carcinoma.

LINK TO TRANSCRIPT

Dr. Monty Pal shares highlights from Day 3 of the 2026 ASCO Annual Meeting, including new research for the treatment of advanced CRC and mCRPC, TIL cell therapy in advanced non-uveal melanoma, and an ultra-low dose immunotherapy trial in head and neck squamous cell carcinoma.

LINK TO FULL TRANSCRIPT

Dr. Monty Pal shares highlights from Day 2 of the 2026 ASCO Annual Meeting, including a practice-changing trial in renal cell carcinoma, advances in ER-positive, HER2-negative early breast cancer, and the use of olanzapine as an effective steroid-sparing alternative for chemo-induced nausea and vomiting in pediatric cancer.

LINK TO FULL TRANSCRIPT

In the first episode of a special daily series during the 2026 ASCO Annual Meeting, Dr. Monty Pal discusses 3 abstracts, including a follow-up on the EV-302 study in urothelial carcinoma, a potential new treatment option for patients with PD-L1-positive advanced non–small cell lung cancer, and a novel psychosocial digital application that improves fatigue and distress in patients with multiple myeloma.

LINK TO FULL TRANSCRIPT